Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine

Journal of International Medical Research

Volumn 41, Issue 1, 2013, Pages 176-187

  Ren, Jianan ^a   Wu, Xiuwen ^a   Liao, Nansheng ^a   Wang, Gefei ^a   Fan, Chaogang ^a   Liu, Song ^a   Ren, Huajian ^a   Zhao, Yunzhao ^a   Li, Jieshou ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Crohn's disease; Crohn's disease activity index (CDAI); Mesalazine; Polyglycoside of Tripterygium wilfordii; Postoperative recurrence; Rutgeerts' score

Indexed keywords

MESALAZINE; PLANT GLYCOSIDE; POLYGLYCOSIDE OF TRIPTERYGIUM WILFORDII; TRIPTERYGIUM WILFORDII EXTRACT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COLON ANASTOMOSIS; COLON RESECTION; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; ILEUM RESECTION; LEUKOPENIA; MAINTENANCE THERAPY; MALE; OUTCOME ASSESSMENT; PHYTOCHEMISTRY; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SURGICAL PATIENT; TREATMENT DURATION;

EID: 84878416366     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060512474744     Document Type: Article

References (24)

1. Shen B. Managing medical complications and recurrence after surgery for Crohn's disease. Curr Gastroenterol Rep 2008; 10: 606-611.
2. Sandborn WJ, Feagan BG and Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007; 26: 987-1003.
3. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006; 55(suppl 1): i36-i58.
4. Becker JM. Surgical therapy for ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1999; 28: 371-390, viii-ix.
5. Tao XL and Lipsky PE. The Chinese antiinflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am 2000; 26: 29-50, viii.
6. Lipsky PE and Tao XL. A potential new treatment for rheumatoid arthritis: thunder god vine. Semin Arthritis Rheum 1997; 26: 713-723.
7. Ren J, Tao Q, Wang X, et al. Efficacy of T2 in active Crohn's disease: a prospective study report. Dig Dis Sci 2007; 52: 1790-1797.
8. Travis SPL, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55(suppl 1): i16-i35.
9. Carter MJ, Lobo AJ and Travis SP. IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53(suppl 5): V1-V16.
10. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 512-530.
11. Regueiro M, Kip KE, Schraut W, et al. Crohn's Disease Activity Index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 2011; 17: 118-126.
12. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-963.
13. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136: 441. e1-450. e1.
14. Swoger JM and Regueiro M. Preventive therapy in postoperative Crohn's disease. Curr Opin Gastroenterol 2010; 26: 337-343.
15. Borowiec AM and Fedorak RN. Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field. Can J Gastroenterol 2011; 25: 140-146.
16. Buisson A, Chevaux JB, Bommelaer G, et al. Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence. Dig Liver Dis 2012; 44: 453-460.
17. Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009; 4: CD006873.
18. Cho SM, Cho SW and Regueiro M. Postoperative management of Crohn disease. Gastroenterol Clin North Am 2009; 38: 753-762.
19. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-659.
20. Tao X, Davis LS, Hashimoto K, et al. The Chinese herbal remedy, T2, inhibits mitogen-induced cytokine gene transcription by T cells, but not initial signal transduction. J Pharmacol Exp Ther 1996; 276: 316-325.
21. Qiu D, Zhao G, Aoki Y, et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kB transcriptional activation. J Biol Chem 1999; 274: 13443-13450.
22. Huang FC, Chan WK, Moriarty KJ, et al. Novel cytokine release inhibitors. Part I: triterpenes. Bioorg Med Chem Lett 1998; 8: 1883-1886.
23. Tao QS, Ren JA, Ji ZL, et al. Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease. Zhonghua Wei Chang Wai Ke Za Zhi 2009; 12: 491-493.
24. Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010; 59: 752-759.